Jiangsu Hengrui Medicine Co., Ltd

DelveInsight's 2025 pipeline analysis reveals 25+ companies developing 28+ therapies for gastrointestinal stromal tumors, indicating strong industry investment in this rare cancer space.

Jiangsu Hengrui Medicine secured inclusion of two products on China's proposed breakthrough therapy list, highlighting their potential to address unmet medical needs in gastric cancer treatment.

DelveInsight's 2025 pipeline report reveals over 20 companies actively developing more than 20 innovative therapies for HER2-positive gastric cancer treatment.

A multicenter retrospective study of 108 patients demonstrated that tislelizumab, with or without tyrosine kinase inhibitors, significantly extended recurrence-free survival in high-risk hepatocellular carcinoma patients after curative resection.

The global thrombocytopenia clinical trials landscape is expanding rapidly with over 25 pharmaceutical companies developing 25+ treatment therapies, according to recent market analysis.

Global hyperuricemia pipeline comprises 12+ key companies developing 15+ treatment therapies across various clinical stages, according to DelveInsight's 2025 report.

The global KRAS inhibitors market has experienced over 400% growth since the first approval in 2021, with four drugs now authorized for treating cancers with KRAS mutations.

• The U.S. Food and Drug Administration has issued a second rejection for the liver cancer combination therapy developed by Jiangsu Hengrui Medicine and HLB, dealing a significant setback to their oncology program. • The combination therapy, targeting advanced hepatocellular carcinoma, failed to meet regulatory standards despite previous promising clinical data in Asian populations. • This rejection highlights the ongoing challenges in developing effective treatments for liver cancer, which remains one of the deadliest cancer types with limited therapeutic options.

• The renal cancer clinical trial pipeline is robust, with over 70 companies developing more than 75 therapies, including novel immunotherapies and targeted agents. • Breast cancer research is also thriving, with over 100 companies exploring 120+ new drugs, such as antibody-drug conjugates and PARP inhibitors, in clinical trials. • Recent FDA actions, including Fast Track and Breakthrough Therapy designations, highlight the potential of emerging therapies for both renal and breast cancer. • Advances in diagnostics, such as PET imaging agents for clear cell renal cell carcinoma, are also contributing to improved management of these diseases.

Several companies are actively developing novel therapies for HER2-mutant non-small cell lung cancer (NSCLC), indicating a robust pipeline.